兰索拉唑与艾塞那肽联用对2型糖尿病患者胃泌素及胃泌酸调节素的影响

doi:10.6040/j.issn.1671-7554.0.2015.338

摘要/Abstract

摘要： 目的观察2型糖尿病(T2DM)患者经艾塞那肽联合兰索拉唑治疗前后糖脂代谢、体成份、胰岛素敏感性的变化;探讨兰索拉唑对T2DM患者血清胃泌素(Gastrin)、胃泌酸调节素(OXM)水平的影响.方法选取肥胖T2DM患者54例,随机分为联合用药组(n=27)和艾塞那肽组(n=27),联合用药组治疗方案:原有降糖基础上应用艾塞那肽10 μg,早晚餐前1 h皮下注射,联合兰索拉唑15 mg,早1片治疗;艾塞那肽组治疗方案:原有降糖基础上应用艾塞那肽10 μg,早晚餐前1 h皮下注射治疗.8周后观察体质量、体成份、血压、空腹血糖(FBG)、血脂、肝肾功、空腹胰岛素、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)、Gastrin、OXM等指标的变化.结果两组患者体质量、体成份、低密度脂蛋白(LDL)、FBG、HbA1c、HOMA-IR、收缩压均较治疗前明显下降(P<0.05).联合用药组胃肠道不良反应较艾塞那肽组减少,Gastrin水平明显升高[(160.76±8.93) vs (95.30±6.01)ng/L, P<0.05],FBG水平[(8.06±2.33) vs (8.51±2.71)mmol/L, P<0.05]、HbA1c水平[(7.79±0.78)% vs (7.87±0.81)%, P<0.05]均低于艾塞那肽组.兰索拉唑治疗前后两组ALT、AST、尿酸(UA)、血肌酐(Scr)、血尿氮(BUN)、高密度脂蛋白(HDL)、OXM等水平差异无统计学意义(P>0.05).相关分析显示艾塞那肽联用兰索拉唑后,Gastrin升高与其HbA1c下降相关(r=-0.302,P<0.05).结论兰索拉唑能改善T2DM患者早期应用艾塞那肽后引起的胃肠道反应,有助于空腹血糖的控制,其作用可能与兰索拉唑提高血清Gastrin水平有关;兰索拉唑对患者血清OXM的变化无明显影响.

关键词: 艾塞那肽, 兰索拉唑, 2型糖尿病, 胃泌素

Abstract: Objective To observe glucose and lipids levels, body composition and insulin sensitivity before and after the treatment of exenatide and lansoprazole in type 2 diabetes mellitus (T2DM) patients, and to explore the effects of lansoprazole on the serum gastrin and oxyntomodulin (OXM). Methods Fifty-four obese patients with T2DM were randomly divided into combined treatment group (n=27) and exenatide group (n=27). Therapeutic plan of combined treatment group: 10 μg exenatide (subcutaneous injection one hour before breakfast and dinner) plus 15 mg lansoprazole were applied based on the original scheme; therapeutic plan of exenatide group: 10 μg exenatide (subcutaneous injection one hour before breakfast and dinner) was applied based on the original scheme. After 8 weeks of treatment, the changes in weight, body composition, blood pressure, fasting blood glucose (FBG), serum lipids, hepatic and renal functions, fasting insulin, glycosylated hemoglobin (HbA1c), insulin resistance index (HOMA-IR), serum gastrin and OXM were measured. Results Body weight, body composition, low densith lipoprotein (LDL), FBG, HbA1c, HOMA-IR and systolic pressure decreased significantly after treatment in both two groups (P<0.05). Comapred withexenatide group, gastrointestinal discomfort was alleviated, serum gastrin level increased [(160.76±8.93) vs (95.30±6.01) ng/L, P<0.05], FBG [(8.06±2.33) vs (8.51±2.71)mmol/L, P<0.05] and HbA1c[(7.79±0.78) vs (7.87±0.81)%, P<0.05] levels decresed in combined treatment group. The changes of ALT, AST, uric acid (UA), serum creatinine (Scr), blood urine nitrogen (BUN), high density lipoprotein (HDL) and OXM in two groups had no statistical differences (P>0.05). Correlation regression analysis showed that the decrease of HbA1c was associated with the increase of gastrin after treatment of exenatide and lansoprazole(r=-0.302, P<0.05). Conclusion Lansoprazole can alleviate gastrointestinal discomfort caused by exenatide in the early stage and reduce the blood glucose levels in obese T2DM patients, which may be related to the increase of gastrin. However, lansoprazole may have not any effects in the changes of oxyntomodulin.

Key words: Type 2 diabetes mellitus, Exenatide, Lansoprazole, Gastrin

中图分类号:

R589

李寒冰, 高燕燕, 李莉, 曹彩霞, 咸玉欣, 王静, 牛佳鹏. 兰索拉唑与艾塞那肽联用对2型糖尿病患者胃泌素及胃泌酸调节素的影响[J]. 山东大学学报（医学版）, 2015, 53(11): 64-68.

LI Hanbing, GAO Yanyan, LI Li, CAO Caixia, XIAN Yuxin, WANG Jing, NIU Jiapeng. Effect of lansoprazole and exenatide on gastrin and oxyntomodulin in patients with type 2 diabetes[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(11): 64-68.

参考文献

[1] Patel V, Joharapurkar A, Dhanesha N, et al. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice[J]. Pharmacol Rep, 2013, 65(4):927-936.
[2] U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years therapy of type Ⅱ diabetes a progressive disease. [J]. Diabetes, 1995, 44(11):1249-1258.
[3] Motoyuki T, Yoshio F, Toyoyoshi U, et al. Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation[J]. Diabetes Investig, 2010, 1(5):172-183.
[4] Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice[J]. Diabetes, 2008, 57(12):3281-3288.
[5] Spencer CM, Faulds D, Lansoprazloe. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders[J]. Drugs, 1994, 48(3):404-430.
[6] Takebayashi K, Sakurai S, Suzuki T, et al. Effect of combination therapy with alogliptin and lansoprazole on glycemic cntrol in patients with type 2 diabetes[J]. Endocr J, 2014, 61(10):1031-1039.
[7] Singh PK, Hota D, Dutta P, et al. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial [J]. J Clin Endocrinol Metab, 2012, 97(11):E2105-E2108.
[8] Bödvarsdóttir TB, Hove KD, Gotfredsen CF, et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes [J]. Diabetologia, 2010, 53(10):2220-2223.
[9] Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes[J]. Medical Hypotheses, 2009, 73(1):29-32.
[10] Yaron S, Judith M, Miri SR, et al. Gastrin: a distinct fate of neurogenin3 positive progenitor cells in the embryonic pancreas [J]. PLoS One, 2013, 8(8): e70397. doi:10.1371/journal.pone.0070397.
[11] Wang M, Racine JJ, Song X, et al. Mixed chimerism and growth factors augment beta cell regeneration and reverse late-stage type 1 diabetes [J]. Sci Transl Med, 2012, 4(133):133-159.
[12] Rooman I, Bouwens L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycemia in C57B16/J mice treated with alloxan[J]. Diabetologia, 2004, 47(2):259-265.
[13] 郭娅棣,高燕燕,李莉,等.兰索拉唑对2型糖尿病患者血糖及胃泌素的影响[J].山东大学学报:医学版, 2013, 51(7): 62-66. GUO Yadi, GAO Yanyan, LI li, et al. Effects of lansoprazole therapy on the plasma glucose and gastrin in the patients with type 2 diabetes mellitus[J]. Journal of Shandong University: Health Sciences, 2013, 51(7):62-66.
[14] Alessandro P. Action and therapeutic potential of oxyntomodulin[J]. Mol Metab, 2014, 3(3):241-251.
[15] Kosinski JR, Hubert J, Carrington PE, et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin[J]. Obesity, 2012, 20(8):1566-1571.
[16] Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes[J]. Vasc Health Risk Manag, 2009, 5(1):199-211.
[17] Macconell L, Brown C, Gurney K, et al. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes:integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials[J]. Diabetes Metab Syndr Obes, 2012, 5:29-41.

相关文章 15

[1]	孟晓梅,郝亚平,王亮,于晓,唐与晓. 血清Isthmin1、Gremlin2水平与2型糖尿病患者视网膜病变的相关性[J]. 山东大学学报 (医学版), 2025, 63(9): 102-107.
[2]	申路佳,逯天威,巩伟明,赵岩松,王淑康,袁中尚. 代谢风险评分在2型糖尿病人群心血管结局预测中的应用[J]. 山东大学学报 (医学版), 2025, 63(8): 69-78.
[3]	陈莹莹,王鲁,胡锡峰,朱高培,薛付忠. 基于贝叶斯网络的2型糖尿病患者并发脑卒中风险预测[J]. 山东大学学报 (医学版), 2025, 63(8): 94-102.
[4]	李金泉,高美芳,闫飞,董明. 136例2型糖尿病患者肌肉痉挛的发生频率及危险因素[J]. 山东大学学报 (医学版), 2023, 61(5): 20-24.
[5]	张天鑫,张婷,黄鑫,韩佳沂,王淑康. 氨基酸与2型糖尿病因果关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2023, 61(5): 102-107.
[6]	韩梅,孟维静,陶子琨,杨希,徐雅琪,穆华夏,卜伟晓,王素珍,石福艳. 基于G-计算的高血压、抑郁在2型糖尿病与认知功能之间的因果多中介分析[J]. 山东大学学报 (医学版), 2023, 61(10): 101-108.
[7]	赵美茹,朱迪,刘淋,管庆波,张栩. 简易胰岛素抵抗指标与698例2型糖尿病患者发生高尿酸血症风险的关联[J]. 山东大学学报 (医学版), 2022, 60(12): 44-51.
[8]	于书卷,王美娟,陈丽,曹英娟,吕晓燕,刘雪燕,林鹏,颜景政. 老年2型糖尿病患者轻度认知功能障碍的影响因素[J]. 山东大学学报 (医学版), 2022, 60(11): 108-112.
[9]	吕丽,姜璐,陈诗鸿,庄向华,宋玉文,王殿辉,安文娟,李倩,潘喆. 210例绝经后2型糖尿病发生骨质疏松的相关因素[J]. 山东大学学报 (医学版), 2021, 59(7): 19-25.
[10]	郑凤杰,宋玉文,孙爱丽,潘喆,王殿辉,娄能俊,吕丽, 庄向华,陈诗鸿. 糖尿病周围神经病变与肌少症的关联性[J]. 山东大学学报 (医学版), 2021, 59(6): 38-44.
[11]	刘萍,宋玉文,王萍,田光伟,郑凤杰,吕丽,杜娇娇,张静,庄向华,陈诗鸿. 维生素D缺乏与2型糖尿病合并抑郁状态的相关性[J]. 山东大学学报 (医学版), 2021, 59(6): 51-56.
[12]	张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[13]	王余余,高丽,陈少华. 94例2型糖尿病患者急性脑梗死后认知障碍与甲状腺功能的关联性[J]. 山东大学学报 (医学版), 2020, 58(5): 56-61.
[14]	金海燕,张炎,马小莉,韩羽,赵蕙琛,刘元涛,张玉超. MiR-122与miR-33a在2型糖尿病合并冠心病患者中的表达[J]. 山东大学学报 (医学版), 2020, 58(3): 94-98.
[15]	唐博,邵静,崔静,孙健平. 2型糖尿病发病与高密度脂蛋白关系的机制研究[J]. 山东大学学报 (医学版), 2020, 58(3): 99-106.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed